LIFECORE BIOMEDICAL, INC. \DE\LFCREarnings & Financial Report
Nasdaq
NextFeb 27, 2026
LFCR Q2 2026 Key Financial Metrics
Revenue
$31.1M
Gross Profit
$7.8M
Operating Profit
$-3.1M
Net Profit
$-10.0M
Gross Margin
25.0%
Operating Margin
-9.9%
Net Margin
-32.1%
YoY Growth
-4.5%
EPS
$-0.29
Financial Flow
LIFECORE BIOMEDICAL, INC. \DE\ Q2 2026 Financial Summary
LIFECORE BIOMEDICAL, INC. \DE\ reported revenue of $31.1M for Q2 2026, with a net profit of $-10.0M (-32.1% margin). Cost of goods sold was $23.3M, operating expenses totaled $10.9M.
Key Financial Metrics
| Total Revenue | $31.1M |
|---|---|
| Net Profit | $-10.0M |
| Gross Margin | 25.0% |
| Operating Margin | -9.9% |
| Report Period | Q2 2026 |
LIFECORE BIOMEDICAL, INC. \DE\ Annual Revenue by Year
LIFECORE BIOMEDICAL, INC. \DE\ annual revenue history includes year-by-year totals (for example, 2025 revenue was $128.9M).
| Year | Annual Revenue |
|---|---|
| 2025 | $128.9M |
| 2024 | $128.3M |
| 2023 | $103.3M |
| 2022 | $185.8M |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $30.1M | $35.7M | $37.9M | $24.7M | $32.6M | $35.2M | $36.4M | $31.1M |
| YoY Growth | -22.3% | 29.4% | 683.9% | 0.7% | 8.0% | -1.5% | -3.8% | -4.5% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $245.8M | $246.2M | $254.0M | $246.8M | $255.4M | $237.7M | $239.3M | $235.2M |
| Liabilities | $203.5M | $186.8M | $200.1M | $207.3M | $195.6M | $190.3M | $191.9M | $198.4M |
| Equity | $1.4M | $17.7M | $11.3M | $-3.9M | $15.4M | $2.2M | $1.3M | $-10.5M |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $1.0M | $-1.5M | $8.6M | $-643000 | $-6.1M | $1.2M | $5.3M | $1.8M |